ARVN Stock — Arvinas Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body’s ow n natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Source: 10-K FY2025 via SEC EDGAR

Share price

$6.41

Market cap

$419.8M

Cash

$558.4M

Enterprise value

-$138.2M

Balance sheet

Cash	$558.4M
Debt	$0.4M
Net cash	$558.0M
Enterprise value	-$138.2M
Basic shares	65.5M shares
Fully diluted shares	82.4M shares
Fully diluted market cap	$528.2M
Cash per share	$8.53
Quarterly burn	$48.3M
Cash runway	11.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

65.4M

Pre-funded warrants

0.0M

Options

9.3M

RSUs

3.6M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

4.2M

FDSO

82.4M

Cap table as of 2026-06-30.

Price history

Loading ARVN daily closes…

Loading price history…

Next catalyst

ARV-393 · Est. Nov 7, 2026 · half midpoint · guided Now

Recently reported

SOC Phase 1 Mixed · 2026-10-07

ARV-102

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	ARV-393 Phase 1 dose escalation in relapsed/refractory NHL · NCT06393738	Phase 1	relapsed/refractory NHL	2H 2026
GUIDEDEst. Nov 7, 2026 Now half midpoint	ARV-806 Phase 1 monotherapy dose escalation in KRAS G12D solid tumors · NCT07023731	Phase 1	KRAS G12D solid tumors	2H 2026
Jan 11 - Feb 22 in 9 wks	ARV-806	Phase 2	KRAS G12D Mutation; Advanced Solid Cancer	—
Jan 15 - Feb 26 in 10 wks	vepdegestrant	Phase 1	Healthy Participants	—
Feb 10 - Mar 24 in 14 wks	Letrozole	Phase 3	Breast Cancer	—
Feb 10 - Mar 24 in 14 wks	ARV-471	Phase 2	Breast Cancer	—
Feb 11 - Mar 25 in 14 wks	vepdegestrant	Phase 2	Breast Cancer	—
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	ARV-027 Phase 1 in healthy volunteers (SBMA/Kennedy’s disease program)	Phase 1	healthy volunteers (SBMA/Kennedy’s disease program)	1H 2027
May 5 - Jun 16 in 6 mo	ARV-471	Phase 2	Breast Cancer	—
Apr 12 - May 24 in 17 mo	ARV-393	Phase 1	Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Vepdegestrant (VEPPANU)

Approved · Active Modality: PROTAC degrader

Aliases ARV-471

Target ER

Partnerships Rigel Pharmaceuticals: exclusive global development, manufacturing and commercialization rights (May 2026); $70.0M upfront + $15.0M transition payment + up to $1.3B in milestones + royalties

Indications

ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer (Approved)

Status note FDA approved in Q2 2026 for ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer after at least one line of endocrine therapy. Rigel responsible for US launch and holds global rights (may sublicense ex-US).

ARV-393

Phase 1 · Active Modality: PROTAC degrader

Target BCL6

Indications

Relapsed/refractory non-Hodgkin lymphoma (NHL) (Phase 1)

Status note In Phase 1 in relapsed/refractory NHL (early monotherapy cohorts; filing notes a higher-than-predicted proportion of T-cell lymphoma patients).

ARV-806

Stage not disclosed · Active Modality: IV PROTAC degrader

Target KRAS G12D

Indications

Pancreatic, colorectal, and non-small cell lung cancer with KRAS G12D mutation (Stage not disclosed)

Status note Investigational IV PROTAC KRAS G12D degrader. Filing groups it among current and/or future clinical trials; phase not explicitly stated. Company plans to seek an out-licensing agreement for additional clinical trials including dose expansion/combination.

ARV-102

Phase 1 · Active Modality: Oral PROTAC degrader

Target LRRK2

Indications

Parkinson's disease (PD) (Phase 1)
Progressive supranuclear palsy (PSP) (Phase 1)

Status note Phase 1 in healthy volunteers (SAD/MAD completed) and in PD patients (SAD enrollment completed Q2 2025; multiple-dose cohort enrollment completed Q4 2025).

ARV-027

Stage not disclosed · Active Modality: PROTAC degrader

Target polyQ androgen receptor (skeletal muscle)

Indications

Spinal bulbar muscular atrophy (SBMA) (Stage not disclosed)

Status note Filing groups it among current and/or future clinical trials; phase not explicitly stated. Filing states the company believes it could become the first treatment option for SBMA (no therapies approved in the US or EU).

Luxdegalutamide

Stage not disclosed · Active Modality: PROTAC (small molecule)

Aliases ARV-766

Target Androgen receptor (AR)

Partnerships Novartis Pharma AG: worldwide development/manufacturing/commercialization license (Apr 2024); $150.0M upfront (paid May 2024) + up to $1.01B in milestones + royalties

Indications

Prostate cancer (Stage not disclosed)

Status note Second-generation PROTAC androgen receptor degrader; fully licensed to Novartis, which is responsible for worldwide clinical development and commercialization. Current clinical phase not stated in the 10-Q excerpts.

AR-V7 program

Preclinical · Active Modality: PROTAC (small molecule)

Target AR-V7 (androgen receptor splice variant)

Partnerships Novartis Pharma AG: AR-V7 program sold via asset purchase agreement (Apr 2024); Novartis holds all research/development/manufacturing/commercialization rights

Indications

not disclosed (Preclinical)

Status note Preclinical PROTAC degrader targeting the AR-V7 androgen receptor splice variant; asset sold to Novartis.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07023731	Phase 2	Active, not recruiting	Sponsor	ARVN	—	KRAS G12D Mutation; Advanced Solid Cancer	2H 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 28-Dec 31)
NCT07749586	Phase 2	Recruiting	Sponsor	ARVN	—	Advanced Solid Tumor	—
NCT06393738	Phase 1	Recruiting	Sponsor	ARVN	—	Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)	2H 2026 Est. Nov 7, 2026 · half midpoint
NCT05909397	Phase 3	Active, not recruiting	Collaborator	PFE	PFE	Breast Cancer	—
NCT05654623	Phase 3	Active, not recruiting	Collaborator	PFE	PFE	Advanced Breast Cancer	—
NCT05573555	Phase 2	Active, not recruiting	Collaborator	PFE	PFE	Breast Cancer	—
NCT06125522	Phase 2	Active, not recruiting	Collaborator	PFE	PFE	Breast Cancer	—
NCT05548127	Phase 2	Active, not recruiting	Collaborator	PFE	PFE	Breast Cancer	—
NCT06206837	Phase 2	Active, not recruiting	Collaborator	PFE	PFE	Breast Cancer	—
NCT07231991	Phase 1	Recruiting	Collaborator	PFE	PFE	Healthy Participants	—
NCT05463952	Phase 1	Active, not recruiting	Collaborator	PFE	PFE	Breast Neoplasms	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 8 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 11 active trials for Arvinas Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	358,257	no change	0.49%	2026-08-14
Stonepine Capital	60,000	+32,500	0.38%	2026-08-17
ADAR1 Capital Management	57,591	no change	0.02%	2026-08-14
Tang Capital Partners	0	-538,658	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ARVN — Arvinas Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

ARVN — Arvinas Inc.